Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

Magnetic Resonance Spectroscopy 44Specimen Handling 38enzalutamide 30Nivolumab 30pembrolizumab 28Docetaxel 23Gemcitabine 22apalutamide 20Prednisone 20Biopsy 20Abiraterone Acetate 18Androgen Antagonists 17cabozantinib 14darolutamide 13abiraterone 13Radiotherapy 13Cisplatin 12enfortumab vedotin 11Radiation 11Ipilimumab 11Pluvicto 10erdafitinib 9belzutifan 9atezolizumab 9X-Rays 9Radiosurgery 9Mitomycin 9olaparib 8cabazitaxel 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PT-100 dipeptide × Genitourinary × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡